Contracts › 75N94025F00001
75N94025F00001: The Contractor Shall Coordinate, Maintain and Manage Nichd Participating Sites for Impaact 2041: Phase I/Ii Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People With Hepatitis C With and Without Hiv.
Awarded to Westat, Inc. by National Institutes of Health (NIH).
$1.1Mobligated
$1.1Mpotential value
31 July 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N94025F00001 |
|---|---|
| Vehicle | 75N94023D00001 |
| Awardee | Westat, Inc. |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Period of performance | 07 March 2025 to 31 July 2028 |
| Potential end | 31 July 2028 |
| Estimated recompete solicitation | ~Q1 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record